Drug Profile
Aflibercept biosimilar - Bioeq
Alternative Names: FYB-203Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Formycon
- Developer Bioeq; Formycon; Klinge Biopharma
- Class Antineoplastics; Eye disorder therapies; Immunoglobulin Fc fragments; Immunoglobulin fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Wet age-related macular degeneration
Most Recent Events
- 31 Dec 2023 Coherus BioSciences terminates its agreement for aflibercept
- 27 Dec 2023 Preregistration for Wet age-related macular degeneration in European Union (Intravitreous)
- 27 Dec 2023 European Medicines Agency accepts marketing authorization application for Aflibercept biosimilar for Wet age-related macular degeneration for review